Sales ramp-up continues (187% y-o-y), +13% vs. ABGSCe Positive EBIT (SEK 324k vs.
FY'24 org. growth outlook downgraded... ...now expecting 5-10% org.
Biovica records consecutive quarterly IVD test sales growth of 40-50%, with good prospects ahead.
Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Biovica records IVD test sales in Q1 of SEK 0.62m, which is 50% above the previous quarter (Q4) and ...
Marimekko’s CMD offered more insights into the company’s SCALE strategy for 2023-2027 and its progre...
Redeye comments on its latest insights regarding regulatory development in India, partly about the r...
Q-linea has signed S.C. Mecro System SRL as a distributor for Romania, which is part of an attractiv...
Redeye provides a brief comment on the changes to CLS’ board of directors.
Aspo’s results have seen ups and downs in recent years, but the stabilized environment and recent in...
Redeye was surprised by today's announcement about CEO Christoffer Abramson stepping down, effective...
Scanfil changes reporting segments to geographical units in 2025.
Redeye comments on an early readout from the intraocular biodistribution study of laquinimod that is...
Cantargia söker finansiering för att inleda en fas 2b-studie med antikroppen nadunolimab på patiente...
Marknadsbearbetningen fortskrider Nettoomsättningen ökade med 5,9 procent, vilket var en lägre öknin...
